EVOGENE LTD (EVGN)
IL0011050551 - Common Stock
Taking everything into account, EVGN scores 3 out of 10 in our fundamental rating. EVGN was compared to 564 industry peers in the Biotechnology industry. EVGN has a bad profitability rating. Also its financial health evaluation is rather negative. EVGN is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year EVGN has reported negative net income.
EVGN had a negative operating cash flow in the past year.
EVGN had negative earnings in each of the past 5 years.
In the past 5 years EVGN always reported negative operating cash flow.
1.2 Ratios
EVGN's Return On Assets of -48.49% is in line compared to the rest of the industry. EVGN outperforms 49.02% of its industry peers.
EVGN's Return On Equity of -647.77% is on the low side compared to the rest of the industry. EVGN is outperformed by 81.11% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.49% | ||
| ROE | -647.77% | ||
| ROIC | N/A |
ROA(3y)-43.55%
ROA(5y)-37.7%
ROE(3y)-115.12%
ROE(5y)-86.46%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of EVGN (81.42%) is better than 87.34% of its industry peers.
The Profit Margin and Operating Margin are not available for EVGN so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 81.42% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
EVGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EVGN has been reduced compared to 1 year ago.
Compared to 5 years ago, EVGN has less shares outstanding
The debt/assets ratio for EVGN is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -9.86, we must say that EVGN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -9.86, EVGN is doing worse than 76.11% of the companies in the same industry.
A Debt/Equity ratio of 3.47 is on the high side and indicates that EVGN has dependencies on debt financing.
EVGN has a worse Debt to Equity ratio (3.47) than 82.71% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.47 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.86 |
ROIC/WACCN/A
WACC6.67%
2.3 Liquidity
A Current Ratio of 4.37 indicates that EVGN has no problem at all paying its short term obligations.
EVGN has a Current ratio (4.37) which is comparable to the rest of the industry.
EVGN has a Quick Ratio of 4.24. This indicates that EVGN is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.24, EVGN perfoms like the industry average, outperforming 48.31% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.37 | ||
| Quick Ratio | 4.24 |
3. Growth
3.1 Past
EVGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.00%, which is quite impressive.
The Revenue has grown by 290.45% in the past year. This is a very strong growth!
Measured over the past years, EVGN shows a very strong growth in Revenue. The Revenue has been growing by 26.37% on average per year.
EPS 1Y (TTM)28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.65%
Revenue 1Y (TTM)290.45%
Revenue growth 3Y75.69%
Revenue growth 5Y26.37%
Sales Q2Q%39.76%
3.2 Future
Based on estimates for the next years, EVGN will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.88% on average per year.
Based on estimates for the next years, EVGN will show a very strong growth in Revenue. The Revenue will grow by 92.80% on average per year.
EPS Next Y29.85%
EPS Next 2Y15.5%
EPS Next 3Y17.88%
EPS Next 5YN/A
Revenue Next Year172.11%
Revenue Next 2Y90.31%
Revenue Next 3Y92.8%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for EVGN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVGN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
EVGN's earnings are expected to grow with 17.88% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.5%
EPS Next 3Y17.88%
5. Dividend
5.1 Amount
EVGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EVOGENE LTD
NASDAQ:EVGN (11/4/2024, 8:06:04 PM)
After market: 2.01 -0.08 (-3.83%)2.09
-0.15 (-6.7%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap10.58M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -48.49% | ||
| ROE | -647.77% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 81.42% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 3.47 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.37 | ||
| Quick Ratio | 4.24 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)28%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y29.85%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)290.45%
Revenue growth 3Y75.69%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y